PURPOSE. Ischemia causes severe and persistent visual loss in many eye diseases, including central retinal vein occlusion (CRVO) and diabetic retinopathy. Activated protein C (APC) has been demonstrated to reduce the cell death associated with ischemia in the brain and kidney. This study was performed to examine the ability of APC to rescue hypoxia-induced retinal cell death in vitro and in vivo.
R etinal ischemia is a major cause of visual impairment and blindness. At the cellular level, ischemic retinal injury consists of a self-reinforcing destructive cascade involving neuronal depolarization, calcium influx, and oxidative stress initiated by energy failure and increased glutamatergic stimulation. The ischemic cascade, once activated, results in cell death, which can occur by the classic and rapid necrotic process or by the slower process of apoptosis. Several animal models and analytical techniques have been used to study retinal ischemia, and an increasing number of treatments have been shown to interrupt the ischemic cascade and attenuate the detrimental effects of retinal ischemia. 1 However, success in the laboratory has not translated to the clinic. Furthermore, neuroprotectionbased treatment strategies for retinal ischemia have so far been disappointing.
To date, there is compelling evidence that activated protein C (APC) could be an ideal neuroprotectant candidate for ischemic stroke therapy. 2 APC, a plasma serine protease with systemic anticoagulant, anti-inflammatory, and antiapoptotic activities, and direct neuronal protective activity, [3] [4] [5] [6] [7] [8] has been shown to attenuate microvascular injury during systemic hypoxia and to reduce tissue hypoxia in traumatized skeletal muscle during endotoxemia. 9, 10 Meanwhile, APC is also believed to protect neurons and neurovascular cells from cell death after transient brain ischemia and embolic stroke in rodents. 4, 6, 7 Therefore, we hypothesize that APC may be a promising therapeutic approach in the treatment of retinal ischemic diseases. Thus, we performed this study to characterize the biological effects of APC in both normoxic and hypoxic conditions, and further investigated whether APC had the ability to block hypoxia-induced cytotoxicity in vitro and in vivo.
METHODS

Reagents
Human plasma-derived APC was kindly provided by the Chemo-Sero-Therapeutic Research Institute (Kumamoto, Japan). Caspase detection kits (SR-VAD-FMK for caspase-3, FAM-LETD-FMK for caspase-8, and FAM-LEHD-FMK for caspase-9) were purchased from Peninsula Laboratories, Inc. (San Carlos, CA). Caspase inhibitors (Z-DEVD-FMK for caspase-3, Z-IETD-FMK for caspase-8, Z-LEHD-FMK for caspase-9) were purchased from BioVision (Mountain View, CA). An in situ terminal deoxynucleotidyl transferasemediated digoxigenin-dUTP nick-end labeling (TUNEL) kit was obtained from Roche Applied Science (Penzberg, Germany).
ARPE-19 and 661w Cell Culture
661w cells, a cell line cloned from retinal tumors of a transgenic mouse demonstrating cellular and biochemical characteristics of cone photoreceptors, 11 were kindly provided by Muayyad R. Al-Ubaidi (University of Oklahoma Health Sciences Center, Oklahoma City, OK). ARPE-19, cultured human retinal pigment epithelial cells, and 661w cells were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 3 mM L-glutamine, 10% fetal bovine serum, 100 U/mL penicillin G, and 100 g/mL streptomycin sulfate at 37°C in an environment containing 95% O 2 and 5% CO 2 . Cell suspensions (4 ϫ 10 5 cells/mL) were seeded onto microplates (tissue culture grade, 96-well, flat bottomed) in a final volume of 100 L culture medium per well. The cells were incubated in 96-well plates overnight to reach 70% to 80% confluence before being exposed to the treatment. 
APC Biological Effects under Normoxic Conditions
Dose-dependent APC biological effects were examined by incubating ARPE-19 and 661w cells with serial concentrations of APC (3, 6, 12, 30, 60, 120 , and 240 g/mL) for 24 hours. To detect the effects over time, the cells were cultured with APC (3, 30, and 120 g/mL) for 0.5 (12 hours), 1, 3, 7 days.
At the indicated time points, the cellular activity of mitochondrial dehydrogenase was measured based on the cleavage of the yellow tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT; Roche Applied Science, Mannheim, Germany).
Hypoxia-Induced Cytotoxicity in RPE and Photoreceptor Cells and Inhibition by APC
Cell suspensions (4 ϫ 10 5 of ARPE-19 and 1 ϫ 10 5 of 661w cells/mL) were seeded onto 96-well microplates in a final volume of 100 L culture medium per well. Hypoxia-related cytotoxicity over time was investigated by placing the cells in an anaerobic chamber (Ͻ1% oxy- 
Caspase-3, -8 and -9 Activities
Caspase activities in ARPE-19 cells cultured for 8 hours under normoxic conditions were used as a control. Caspase activity in hypoxic conditions was detected by placing ARPE-19 cells into an anaerobic chamber for 8 hours. Then, 3.3 L of 30ϫ caspase detection reagents (SR-VAD-FMK for caspase-3, FAM-LETD-FMK for caspase-8, FAM-LEHD-FMK for caspase-9) were added per 100 L of sample volume. After 1 hour of incubation at 37°C, a fluorescent microscope and a fluorescent plate reader were used to visualize and analyze the activities of caspase-3, -8 and -9. The ratio of optical density (OD) of experimental groups to that of control was used to represent the caspase activity.
To evaluate the effect of caspase inhibition, caspase inhibitors (Z-DEVD-FMK for caspase-3, Z-IETD-FMK for caspase-8, and Z-LEHD-FMK for caspase-9) were added to the culture medium for 8 hours under hypoxic conditions. Then, an MTT assay was performed to determine cell viability.
APC Effects on Hypoxia-Induced Caspase Activation
ARPE-19 cells were placed into an anaerobic chamber with APC (3, 6, 12, and 30 g/mL) for 8 hours. Then caspase activities were evaluated as just described.
In Vivo CRVO Model
We used pigmented rats weighing from 150 to 200 g. All animals were treated in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. The CRVO model was established as previously described. 12, 13 Briefly, immediately after an injection of rose bengal (2 mg/kg; Nacalai Tesque, Kyoto, Japan) into the tail vein, a laser was applied to the major retinal veins adjacent to the optic nerve head to induce a thrombus. The laser settings were as follows: wavelength, 514 nm; spot size, 50 m; power, 100 mW; duration, 0.5 second; and number of applications, one to three shots for each vein. Retinal vein occlusion was confirmed by fluorescein angiography, and eyes with hemi-CRVO or BRVO were excluded from the study. One hour after CRVO induction, 2 L of balanced salt solution (BSS, Alcon, Kyoto, Japan) or APC (0.03 g/L or 0.3 g/L) were intravitreally injected into the eyes (n ϭ 6 for each group). The final concentrations of APC (ϳ3 and 30 g/mL), were calculated based on a previously reported method. 14 Twenty-four hours after intravitreal injection, the rats were euthanatized with an overdose of ketamine. Immediately after euthanatization, the eyes were enucleated and fixed with 4% paraformaldehyde in phosphate-buffered saline at 4°C overnight. Then, 8-m cryosections across the optic disc and the injection site were stained using the TUNEL method. Ten sections from each eye were stained, and the number of all TUNEL-positive cells in each section was counted manually under a microscope, except for those cells within a disc diameter from the optic disc, which were directly damaged by laser irradiation.
Statistical Analysis
All experiments were repeated at least four times, and the results are expressed as the means Ϯ standard deviations (SDs). One-way analysis of variance followed by least-significant difference (LSD) t-test was used to evaluate the significance of any differences, and P Ͻ 0.05 was considered statistically significant.
RESULTS
Biological Effects of APC on Normoxic ARPE-19 and 661w Cells
Lower concentrations of APC (3-60 g/mL) showed a cell protective effect, whereas higher concentrations of APC (Ն120 g/mL) developed cytotoxicity in both ARPE-19 and 661w cells ( Fig. 1A ; Table 1A ). APC at lower doses (3 and 30g/mL) showed no cytotoxicity on normoxic ARPE-19 and 661w cells over time, however, APC at higher doses (Ն120 g/mL) showed significant cytotoxicity in the first 12 hours, and increased dramatically over time (Fig. 1B, Table 1B ).
Hypoxia-induced Cytotoxicity and Cytoprotection of APC on Hypoxic ARPE-19 and 661w Cells
In normoxic conditions, no cell death was observed in 24 hours. When ARPE-19 and 661w cells were cultured in an anaerobic chamber, cell death developed in a time-dependent manner (Fig. 1C , Table 1C ). The most significant cell death induced by hypoxia was observed after 8 hours of treatment. APC ranging from 0.3 to 30 g/mL significantly protected ARPE-19 and 661w cells from hypoxia-induced cell death, and APC-mediated cytoprotection had no obvious difference due to the concentrations of the applied doses (Fig. 1C , Table 1C ).
Involvement of Caspase-3, -8, and -9 in Hypoxia-Induced Cytotoxicity
After ARPE-19 cells were incubated in an anaerobic chamber for 8 hours, the activation of caspase-3, -8, and -9 was observed ( Fig. 2A-G ; Table 2A ). When inhibitors of caspase-3, -8, and -9 were added to the culture medium, hypoxia-induced cell death was significantly reduced (Fig. 2H, Table 2B ). There was no observed difference in the reduction of cell death between the inhibitors of caspase-8 and -9; however, caspase-3 inhibition showed a less protective effect (P Ͻ 0.05).
APC-Mediated Inhibition of Caspase Activity In Vitro
APC dosages ranging from 3 to 30 g/mL totally abolished hypoxia-induced activation of caspase-3, -8, and-9 ( Fig. 3 , Table 3 ). There were no observed differences in caspase inhibition effects due to the various APC concentrations. These results strengthen the evidence that APC may protect cells from hypoxia-induced death by inhibiting caspase pathways. 
Hypoxia-Induced Apoptosis and APC-Mediated Cytoprotection in a CRVO Model
Few TUNEL-positive cells were detected in normal rat retinas, whereas a significant increase in the number of TUNEL-positive cells ( Fig. 4 , P Ͻ 0.01, Table 4 ) was observed in the experimental CRVO eyes injected with balanced salt solution. Apoptotic cells were mainly located in the outer nuclear layer but seldom in the other layers. Ischemia-associated apoptosis was reduced dramatically by intravitreal injection of APC at lower (3 g/mL) and higher (30 g/mL) doses (P Ͻ 0.01). There were no significant differences (P Ͼ 0.05) between the two applied concentrations of APC. No extra morphologic damage was caused by APC injection.
DISCUSSION
Occlusion of retinal vessels leading to retinal ischemia is a feature shared by several disease processes including central retinal vein occlusion (CRVO), branch retinal vein occlusion (BRVO), diabetic retinopathy (DR), and retinopathy of prematurity (ROP), diseases that are collectively referred to as ischemic retinopathies. 15 An interruption in the supply of blood to the retina leads to tissue ischemia, which causes rapid failure of energy production and subsequent cell death through necrosis or apoptosis. The optimal therapy should have the benefit of restoring the normal retinal environment as well as preventing irreversible retinal damage.
APC, which is neuroprotective during transient ischemia 3, 16 and promotes activation of antiapoptotic mechanisms in brain cells by acting directly on endothelium and neurons, 3, 5, 6, 8 may be a promising candidate to treat ischemic retinopathy. To our knowledge, there has been no investigation of the biological effects of APC on retina and retinal cells, to date. In our study, APC was found to have two contrary effects on cultured normoxic ARPE-19 and 661w cells, according to the applied dosage. APC at a dose of lower than 60 g/mL had protective effects, whereas APC at a dose of higher than 120 g/mL induced significant cytotoxicity.
In our in vitro experiment, viability of ARPE-19 and 661w cells in the presence of hypoxia was related to the duration of exposure. APC dosages ranging from 0.3 to 30 g/mL were demonstrated to protect against hypoxia-induced cell death. This result agrees with those in previous studies of other tissues that have shown that APC prevents glucose-induced apoptosis in endothelial cells and podocytes in diabetic nephropathy, and that APC blocks p53-mediated apoptosis in ischemic human brain endothelium. 3, 17 APC possibly reduces hypoxia-induced cell death by inhibiting the activation of caspase-3, -8, and -9. Our speculation is supported by previously reported data that APC blocks caspase-3, -8, and -9 activation in hypoxic brain endothelial cells. 7 The caspases, a family of cysteine proteases and the central regulators of apoptosis, have been demonstrated to play an important role in ischemia-induced cytotoxicity in vivo and in vitro. 7,18 -21 Initiator caspases, including caspase-8 and -9, are closely coupled to proapoptotic signals. Once activated, these caspases cleave and activate downstream effector caspases, including caspase-3, -6, and -7, which in turn execute apoptosis by cleaving cellular proteins containing specific Asp residues. In this study, caspase-3, -8, and -9 were significantly activated by hypoxia. Yang et al. 22 reported that caspase-8 level in ARPE-19 cells was low, whereas we found elevation of caspase-8 in those cells. This discrepancy may be caused by the differences in induction; TNF-␣ was used in their study and hypoxia in our study. Inhibition of caspase-3, -8, or -9 produced a good protective effect on hypoxia-treated ARPE-19 cells, with no significant difference of protective effects between inhibition of caspase-8, -9, or both -8 and -9. Inhibition of caspase-8 or -9 retained a higher rate of viable cells than inhibition of caspase-3 did, suggesting that other candidates besides caspase-3, such as caspase-6 and -7, downstream of caspase-8 and -9, may be activated and contribute to hypoxia-mediated cell death.
Next, we studied whether our findings in vitro translate in vivo by using a rat model of CRVO. Experimental CRVOinduced ischemia alone was shown to produce significant cell death, whereas APC, which was applied at two dosages (3 and 30 g/mL) and demonstrated no cytotoxicity in vitro, had the ability to block apoptosis induced by CRVO-derived ischemia. Dead cells in CRVO retina were far more prevalent in the ONL than in other retinal layers, which may be due to the higher sensitivity of photoreceptor cells to retinal ischemia than other retinal cells. 2, 23 Our results are in good agreement with previous data showing that APC is neuroprotective during ischemia in vivo. 2, 3, 5, 16 Several clinical studies argue that some patients with CRVO exhibit APC resistance, but large-sample epidemiologic studies have proven that APC resistance has no major role in the pathogenesis of CRVO and other venous thrombosis diseases. 24 -26 Thus, we believe that this study will translate well to patients with CRVO in vivo. In summary, our data show that APC has a protective effect on ischemia-induced cytotoxicity both in vivo and in vitro. Therefore, APC may hold great promise in the treatment of ischemic retinal diseases.
